Posted on 27/01/2010 in Pharmaceutical Company Financials Novartis this week published its financial results for the whole of 2009.
The data reveals that the firm's net sales during the period rose by 11 per cent in local currencies.
This is something it attributes to pharmaceuticals driving growth and the sale of more than 100 million influenza A H1N1 vaccine doses.
Additionally, the organisation's net income rose by eight per cent to $10.3 billion (6.38 billion pounds), it revealed.
Last year, Novartis also completed the transition from one chief executive officer to another as it welcomed Joe Jimenez as the head of its "simplified leadership organisation".
The firm added that it also delivered "sustained business expansion and profit improvement with all divisions contributing to [a] strong performance".
In other Novartis news, last week the company announced that FTY720 (fingolimod) showed significant efficacy in reducing relapses, disability progression and MRI lesions in multiple sclerosis patients.
Regulatory approval for the drug was submitted to the EU last month. Other news stories from 27/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
